MOTS-c: The Exercise-Mimetic Mitochondrial Peptide

Peptides and Exercise Performance

16 amino acids

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK, improves insulin sensitivity, and mimics key metabolic effects of exercise in animal models.

Lee et al., Cell Metabolism, 2015

Lee et al., Cell Metabolism, 2015

View as image

Your mitochondria make their own signaling peptides. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is the most studied of these mitochondrial-derived peptides, a 16-amino-acid molecule encoded not by nuclear DNA but by the mitochondrial genome. Discovered in 2015 by Lee et al. at the University of Southern California, MOTS-c made headlines because it appeared to mimic exercise at the molecular level: activating AMPK, improving insulin sensitivity, and preventing diet-induced obesity in mice without any physical activity.^[1] That discovery positioned MOTS-c as a potential "exercise in a pill," a concept that connects it to the broader landscape of exercise-mimetic compounds and AICAR research. The science has since matured considerably, revealing both the depth of MOTS-c's biology and the distance remaining between animal data and human therapeutics.

What MOTS-c is and where it comes from

MOTS-c is encoded within the 12S ribosomal RNA gene of mitochondrial DNA. Unlike the vast majority of known peptides, which are encoded by nuclear genes, MOTS-c originates from the mitochondrial genome, a small circular chromosome inherited exclusively from the mother. This makes MOTS-c one of a small family of mitochondrial-derived peptides (MDPs) that includes humanin and SHLP1-6.^[2]

The peptide's sequence (MRWQEMGYIFYPRKLR) is highly conserved across species, suggesting it performs a fundamental biological function that has been maintained through evolution. Lee et al. (2016) characterized MOTS-c as a novel regulator of muscle and fat metabolism, establishing that it is detectable in plasma and that its levels change in response to metabolic stress.^[2]

The fact that mitochondria produce their own signaling peptides was itself a paradigm shift. Mitochondria were understood as energy-producing organelles; the discovery that they also generate hormonal signals that regulate systemic metabolism reframed them as active endocrine participants. Zheng et al. (2023) reviewed the therapeutic implications, noting that MOTS-c's mitochondrial origin gives it a unique signaling axis that nuclear-encoded peptides cannot replicate.^[4]

How MOTS-c activates AMPK

MOTS-c's primary signaling mechanism involves AMPK (AMP-activated protein kinase), the cell's master energy sensor. AMPK is activated when cellular energy levels drop, as occurs during exercise, fasting, or metabolic stress. Once active, AMPK triggers a cascade of metabolic adaptations: increased glucose uptake, enhanced fatty acid oxidation, improved mitochondrial biogenesis, and suppressed anabolic pathways that consume energy.

Lee et al. (2015) showed that MOTS-c activates AMPK in skeletal muscle cells, producing metabolic effects that overlap with those of exercise. Treated mice on a high-fat diet showed improved glucose tolerance, reduced fat mass, and prevention of diet-induced obesity, all without increasing physical activity.^[1]

Kim et al. (2019) deepened the picture by showing that MOTS-c acts as a regulator of plasma metabolites and enhances insulin sensitivity through effects on the methionine-folate cycle and purine biosynthesis. MOTS-c treatment shifted the metabolomic profile of treated animals toward a pattern resembling exercise-trained animals, with changes in AICAR accumulation and downstream 5-aminoimidazole-4-carboxamide ribonucleotide levels that drive AMPK activation.^[5]

Gudiksen et al. (2026) provided the most mechanistically detailed study to date, demonstrating that MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency through a PGC-1alpha/AMPK-dependent mechanism. This confirmed that MOTS-c does not simply activate a single pathway but orchestrates a coordinated improvement in mitochondrial function that parallels the adaptations seen with regular exercise training.^[6]

Exercise increases circulating MOTS-c

If MOTS-c mimics exercise, does exercise itself produce more MOTS-c? The answer is yes.

Von Walden et al. (2021) measured circulating mitochondrial-derived peptide levels in humans before and after acute endurance exercise. MOTS-c levels rose within 30 minutes of a cycling bout, peaked during the exercise session, and returned toward baseline within 4 hours. This temporal pattern is consistent with MOTS-c acting as an exercise-responsive signal, released by working muscles and circulating to influence systemic metabolism.^[7]

Reynolds et al. (2021) extended this finding by showing that MOTS-c is an exercise-induced regulator of age-dependent physical decline. In mice, exercise increased MOTS-c levels in skeletal muscle and plasma. Exogenous MOTS-c administration in sedentary aged mice improved physical capacity, enhanced skeletal muscle homeostasis, and reduced markers of muscle aging. The treated mice performed as if they had been exercise-trained, despite never running on a wheel.^[8]

Yang et al. (2021) asked whether MOTS-c and exercise produce additive benefits. In mice fed a high-fat diet, they tested MOTS-c alone, exercise alone, and MOTS-c plus exercise. The combination produced synergistic improvements: insulin resistance improved more than with either intervention alone, PGC-1alpha expression was higher, and mitochondrial function markers exceeded the additive prediction from each individual treatment. This suggests MOTS-c and exercise work through overlapping but not identical pathways.^[4]

MOTS-c, aging, and muscle function

The relationship between MOTS-c and aging is counterintuitive. Unlike most biological signals that decline with age, MOTS-c expression in skeletal muscle appears to increase in healthy aging.

D'Souza et al. (2020) measured MOTS-c expression in skeletal muscle biopsies from healthy men across a range of ages. Older men with higher MOTS-c expression had better walking speed and grip strength than those with lower expression. The authors proposed that MOTS-c upregulation represents a compensatory response to age-related mitochondrial decline: as mitochondrial function deteriorates, the organelle increases its MOTS-c signal to maintain metabolic homeostasis.

This finding reframes MOTS-c from a simple exercise-mimetic into a potential biomarker of mitochondrial health. Individuals whose mitochondria mount a robust MOTS-c response to age-related stress maintain better physical function than those whose response is blunted.

Wan et al. (2023) reviewed the aging evidence and noted that MOTS-c levels in plasma decline with age in some populations, even as muscle expression may increase. This tissue-specific pattern suggests that circulating MOTS-c and intracellular MOTS-c may have different regulatory roles and different trajectories during aging.^[3]

Insulin sensitivity and metabolic disease

The insulin-sensitizing effects of MOTS-c extend beyond diet-induced obesity.

Yin et al. (2022) tested MOTS-c in a gestational diabetes mellitus (GDM) model and found that it relieved hyperglycemia and insulin resistance. This is a condition where standard exercise-based interventions are difficult to implement, making a peptide that mimics exercise effects particularly relevant. MOTS-c treatment reduced fasting glucose, improved glucose tolerance, and restored insulin signaling in placental and muscle tissue. The GDM model is particularly informative because it isolates MOTS-c's metabolic effects from the confounding variable of physical activity changes, since the pregnant animals were not exercising. The glucose-lowering effect was comparable in magnitude to what moderate exercise produces in similar models, reinforcing the "exercise-mimetic" designation.

Kim et al. (2019) demonstrated that MOTS-c enhances insulin sensitivity through regulation of the methionine-folate cycle, connecting mitochondrial function to one-carbon metabolism. This metabolic link suggests that MOTS-c's effects on insulin sensitivity are not simply downstream of AMPK activation but involve a distinct metabolic pathway that intersects with folate metabolism and nucleotide synthesis.^[5]

The Kim et al. (2018) nuclear translocation study added another dimension. Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus, where it directly regulates nuclear gene expression. This means a mitochondrially encoded peptide can reprogram nuclear transcription, creating a retrograde signaling pathway from mitochondria to nucleus that coordinates cellular metabolism across both genomes.^[9] This nuclear translocation is stress-dependent: MOTS-c remains cytoplasmic under normal conditions and only moves to the nucleus when cells face metabolic challenges such as glucose deprivation or oxidative stress. Once in the nucleus, MOTS-c binds to antioxidant response element (ARE) motifs and regulates genes involved in glutathione metabolism and cellular stress defense. This dual localization, cytoplasmic under normal conditions and nuclear under stress, makes MOTS-c function as both a metabolic regulator and a stress-response coordinator.

Genetic variation: the m.1382A>C polymorphism

Not everyone's MOTS-c is identical. Lee et al. (2021) identified a pro-diabetogenic mitochondrial DNA polymorphism (m.1382A>C) that alters the MOTS-c peptide sequence. This variant is predominantly found in East Asian populations and is associated with increased risk of type 2 diabetes. The altered MOTS-c peptide has reduced biological activity compared to the wild-type sequence.

This finding has two implications. First, it validates MOTS-c as functionally important in human metabolism: a natural variant that weakens MOTS-c function leads to metabolic disease. Second, it introduces population-level variation into any therapeutic strategy based on MOTS-c, since the peptide's effectiveness may differ based on the recipient's mitochondrial genotype.

What MOTS-c cannot do (yet)

The MOTS-c literature has a significant gap: almost all data comes from cell culture and rodent models. No randomized controlled trial has tested MOTS-c in humans.

The animal data is consistent and reproducible across multiple labs and models (diet-induced obesity, gestational diabetes, aging), which strengthens confidence in the biology. But translating a mitochondrially encoded peptide from mice to humans involves unknowns that preclinical data cannot address: optimal dosing, route of administration, half-life in human circulation, potential immunogenicity, and long-term safety.

MOTS-c is not FDA-approved for any indication. It is available through research chemical suppliers, but its use outside of research settings is not supported by human clinical evidence. The World Anti-Doping Agency (WADA) has not specifically listed MOTS-c, but peptide hormones and growth factors are broadly prohibited, and exercise-mimetic compounds fall under scrutiny. The intersection of peptides and exercise performance raises similar regulatory questions across the category.

The connections between MOTS-c and NAD+ metabolism are still being worked out. Whether MOTS-c supplementation produces the same metabolic benefits as endogenous MOTS-c production from exercise is an open question. The synergistic data from Yang et al. (2021) suggests supplementation could enhance exercise benefits, but the longevity implications remain speculative without human data.

The Bottom Line

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK, improves insulin sensitivity, and mimics key metabolic adaptations of exercise in animal models. Circulating MOTS-c levels rise during endurance exercise in humans, and the peptide improves physical function and muscle homeostasis in aged mice. A natural genetic variant that weakens MOTS-c function is associated with increased type 2 diabetes risk, validating its metabolic importance. No human clinical trial has tested MOTS-c therapeutically. The animal evidence is consistent across multiple disease models, but the gap between preclinical data and clinical application remains the defining limitation of this field.

Frequently Asked Questions

What is MOTS-c peptide?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by mitochondrial DNA, not nuclear DNA. Discovered by Lee et al. in 2015, it activates the AMPK energy-sensing pathway, improves insulin sensitivity, and produces metabolic effects in animals that resemble those of exercise. It belongs to a family of mitochondrial-derived peptides that includes humanin.^[1]

Does exercise increase MOTS-c levels?

Yes. Von Walden et al. (2021) measured circulating MOTS-c in humans and found that levels rose within 30 minutes of a cycling bout and returned to baseline within 4 hours. Reynolds et al. (2021) showed that exercise increases MOTS-c in both muscle tissue and plasma in mice, and that exogenous MOTS-c in sedentary aged mice produced exercise-like improvements in physical capacity.^[7]

How does MOTS-c improve insulin sensitivity?

MOTS-c activates AMPK, the same energy-sensing enzyme activated by exercise and metformin. Kim et al. (2019) showed it also regulates the methionine-folate cycle, affecting one-carbon metabolism and nucleotide synthesis. In mice, MOTS-c treatment prevented diet-induced insulin resistance and reduced fasting glucose. Yin et al. (2022) extended these findings to gestational diabetes models.^[5]

Is MOTS-c an exercise replacement?

In animal models, MOTS-c reproduces some metabolic effects of exercise without physical activity: improved glucose tolerance, reduced fat mass, enhanced mitochondrial function. However, Yang et al. (2021) showed that MOTS-c plus exercise produced synergistic benefits exceeding either alone, suggesting the peptide complements rather than replaces exercise. No human data exists to assess this question clinically.^[4]

Does MOTS-c decline with aging?

The answer depends on which tissue. D'Souza et al. (2020) found that skeletal muscle MOTS-c expression actually increases with healthy aging and correlates with better physical function. Plasma levels, however, may decline. This suggests MOTS-c upregulation in muscle is a compensatory response to age-related mitochondrial dysfunction, and individuals whose mitochondria mount this response maintain better function.

Is MOTS-c approved for human use?

No. MOTS-c is not FDA-approved for any indication. All published efficacy data comes from cell culture and animal models. No randomized controlled trial has tested MOTS-c in humans. It is available through research chemical suppliers but its use outside of research is not supported by clinical evidence. The 2026 Gudiksen et al. study confirmed the AMPK mechanism but used mouse muscle models.^[6]